ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 938,05
0,40%
Dow Jones
44 713,58
0,65%
DAX
21 416,27
0,64%
Brent Oil
76,745
0,62%
Bitcoin
102 747,25
0,66%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Biomea Fusion Inc (BMEA)

  7. Biomea Fusion Inc (BMEA) Actualités

BMEA

Biomea Fusion (BMEA)

Biomea Fusion Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:BMEA
DateHeureSourceTitreSymboleSociété
15/01/202522h57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BMEABiomea Fusion Inc
13/01/202515h00GlobeNewswire Inc.Biomea Fusion to Become a Diabetes & Obesity Medicines CompanyNASDAQ:BMEABiomea Fusion Inc
07/01/202515h00GlobeNewswire Inc.Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination StudyNASDAQ:BMEABiomea Fusion Inc
06/01/202522h57Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BMEABiomea Fusion Inc
06/01/202513h00GlobeNewswire Inc.Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BMEABiomea Fusion Inc
17/12/202414h10GlobeNewswire Inc.Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
17/12/202400h15GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)NASDAQ:BMEABiomea Fusion Inc
12/12/202423h02GlobeNewswire Inc.Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)NASDAQ:BMEABiomea Fusion Inc
09/12/202422h01GlobeNewswire Inc.Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
06/12/202414h00GlobeNewswire Inc.Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaNASDAQ:BMEABiomea Fusion Inc
02/12/202422h05GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
18/11/202414h00GlobeNewswire Inc.Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
30/10/202421h00GlobeNewswire Inc.Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateNASDAQ:BMEABiomea Fusion Inc
29/10/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BMEABiomea Fusion Inc
29/10/202421h46GlobeNewswire Inc.Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
21/10/202415h00GlobeNewswire Inc.Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219NASDAQ:BMEABiomea Fusion Inc
15/10/202422h05GlobeNewswire Inc.Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RNASDAQ:BMEABiomea Fusion Inc
07/10/202415h00GlobeNewswire Inc.Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)NASDAQ:BMEABiomea Fusion Inc
01/10/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BMEABiomea Fusion Inc
01/10/202415h00GlobeNewswire Inc.Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes ExpertsNASDAQ:BMEABiomea Fusion Inc
26/09/202420h00GlobeNewswire Inc.FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes TrialsNASDAQ:BMEABiomea Fusion Inc
31/07/202422h05GlobeNewswire Inc.Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
06/06/202422h05GlobeNewswire Inc.Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical HoldNASDAQ:BMEABiomea Fusion Inc
30/05/202415h12GlobeNewswire Inc.Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesNASDAQ:BMEABiomea Fusion Inc
02/05/202422h05GlobeNewswire Inc.Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
01/05/202422h10GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
01/04/202415h02GlobeNewswire Inc.Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219NASDAQ:BMEABiomea Fusion Inc
01/04/202415h00GlobeNewswire Inc.Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:BMEABiomea Fusion Inc
06/03/202409h04GlobeNewswire Inc.Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic FunctionNASDAQ:BMEABiomea Fusion Inc
01/03/202422h16GlobeNewswire Inc.Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BMEABiomea Fusion Inc
 Showing the most relevant articles for your search:NASDAQ:BMEA

Dernières Valeurs Consultées

EU
CAP
Capgemini
NASDAQ
GOOGL
Alphabet
NYSE
KO
Coca Cola
NASDAQ
MSFT
Microsoft
COIN
DOGEUSD
Dogecoin
EU
EN
Bouygues
EU
RI
Pernod Ricard
COIN
ADAUSD
Cardano
EU
DG
Vinci
EU
ORA
Orange
NYSE
MRK
Merck
NYSE
NKE
Nike
FTSE
UKX
FTSE 100
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés